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Abstract
Introduction
Conservative treatment solutions against aortic prosthetic vascular graft infection (APVGI)
for inoperable patients are limited. The combination of antibiotics with antibacterial helper
compounds, such as the neuroleptic drug thioridazine (TDZ), should be explored.
Aim
To investigate the efficacy of conservative systemic treatment with dicloxacillin (DCX) in
combination with TDZ (DCX+TDZ), compared to DCX alone, against early APVGI caused
by methicillin-sensitive Staphylococcus aureus (MSSA) in a porcine model.
Methods
The synergism of DCX+TDZ against MSSA was initially assessed in vitro by viability assay.
Thereafter, thirty-two pigs had polyester grafts implanted in the infrarenal aorta, followed by
inoculation with 106 CFU of MSSA, and were randomly administered oral systemic treat-
ment with either 1) DCX or 2) DCX+TDZ. Treatment was initiated one week postoperatively
and continued for a further 21 days. Weight, temperature, and blood samples were collected
at predefined intervals. By termination, bacterial quantities from the graft surface, graft
material, and perigraft tissue were obtained.
Results
Despite in vitro synergism, the porcine experiment revealed no statistical differences for
bacteriological endpoints between the two treatment groups, and none of the treatments
eradicated the APVGI. Accordingly, the mixed model analyses of weight, temperature, and
blood samples revealed no statistical differences.
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Conclusion
Conservative systemic treatment with DCX+TDZ did not reproduce in vitro results against
APVGI caused by MSSA in this porcine model. However, unexpected severe adverse
effects related to the planned dose of TDZ required a considerable reduction to the adminis-
tered dose of TDZ, which may have compromised the results.
Introduction
Aortic prosthetic vascular graft infection (APVGI) is a serious and therapeutically challenging
complication. In earlier series, mortality and lower-limb amputation rates are reportedly up to
88% and 25%, respectively [1–3]. Methicillin-sensitive Staphylococcus aureus (MSSA) is the
most frequently isolated bacteria in the early phase (4 months) of APVGIs, accounting for
43–64% of the isolates [4, 5]. New treatment regimens involving complete in situ graft replace-
ment with an autogenous conduit or allograft have lowered mortality and reinfection rates
considerably [1, 6]. Nonetheless, patients with APVGIs are often elderly with comorbidities,
who may not be eligible for open surgery. Furthermore, an increasing number of inoperable
patients are treated with endovascular aortic repair (EVAR), and infections related to endo-
prosthetic grafts in this category of patients render them less favourable for open surgery. Con-
sequently, conservative treatment with antibiotic only and complete graft preservation in high
risk patients has been evaluated with limited rates of success [7–10]. The insufficient effect of
conservative APVGI treatment is probably a combination of low antibiotic bioavailability at
the infection site and the formation of a protective biofilm layer, which significantly reduces
the susceptibility of the microorganism [11, 12]. The use of a helper compound, such as the
antipsychotic drug thioridazine (TDZ), can significantly potentiate the antibacterial efficacy of
β-lactam antibiotics against both methicillin-resistant and susceptible S. aureus strains and
induces a synergetic effect in vitro [13–16]. On the other hand, conflicting results have been
obtained in animal studies comprising C. elegans and mice [17–19]. The antibacterial mecha-
nisms of TDZ are not completely understood, but it is known to induce major changes in tran-
scription of genes related to pathways in cell wall biosynthesis [20, 21]. Furthermore, static in
vitro experiments indicate that TDZ reduces staphylococcal biofilm formation by inactivation
of efflux pumps [22] and enhanced loading capacity of DCX when co-loaded with TDZ into a
polymer hybrid silicone material [23], making the combination of TDZ and a β-lactam antibi-
otic a particularly interesting option for the management of APVGIs caused by S. aureus.
The aim of this study was to investigate the efficacy of conservative systemic treatment of
TDZ in combination with dicloxacillin (DCX), compared to DCX alone, against early APVGI
caused by MSSA in a porcine model. Initially, we determined the in vitro efficacy of combining
DCX and TDZ against the MSSA test strain. The in vivo efficacy was evaluated primarily in
terms of bacteriological endpoints and secondarily by changes in weight, temperature, white
blood cell count (WBC), haemoglobin, and haptoglobin. Finally, we report on observations
concerning animal welfare, treatment compliance, and adverse drug effects.
Materials and methods
Antimicrobial agents
For the in vitro experiments we used DCX (Sigma-Aldrich Corporation, Denmark) and TDZ
(thioridazine hydrochloride, Sigma-Aldrich Corporation, Denmark) in its racemic form. For
the in vivo experiments DCX capsules (Dicillin1 250 mg; Sandoz, Denmark) were purchased
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and used as commercially registered in Denmark for clinical use [24]. The purchase of TDZ
tablets (Thioridazin-neuraxpharm1 25 mg; thioridazine hydrochloride, Neuraxpharm, Ger-
many) was licenced by the Danish Health and Medicines Authority (reference no.:
2013041542).
Bacterial test strain
Throughout this study, MSSA (ATCC 29213) was utilized. This strain had previously been
used and validated by Gao et al. in a similar porcine model [25–27]. The strain was susceptible
to oxacillin, gentamicin, ciprofloxacin, rifampicin, vancomycin and cefoxitin, but resistant to
penicillin.
MIC, MBC and viability assay
Minimal inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)
tests were respectively performed for DCX and TDZ according to Clinical Laboratory Stan-
dards Institute guidelines, and effects on bacterial growth of DCX and TDZ alone and in com-
bination were tested by a viability assay as previously reported by Klitgaard and colleagues
[13].
Animals
We used domestic female pigs from a specific-pathogen-free herd at the Department of Ani-
mal Science, Aarhus University. All pigs were approximately three and half months old at the
beginning of the experiment. During the entire study period the pigs were housed individually
in pens with saw-dusted solid floors and drinking nipples. They were fed three times daily. All
pigs were acclimatized under these conditions for at least one week before initiation of the
experiment. The animal study protocol was approved by the Danish Animal Experimentation
Inspectorate (license no. 2012-15-2934-00290).
The APVGI porcine model
The APVGI porcine model was carried out as a part of a tandem project performed in the
same series of pigs involving a central venous catheter infection model [23]. Inoculation and
implantation of the aortic grafts and central venous catheters were performed during the same
operation using the same MSSA strain (ATCC 29213).
The anaesthetic and surgical procedure has previously been described [25–27]. In brief,
pigs were placed in a supine position and the surgical area was prepared with alcohol-based
chlorhexidine and sterile dressings. All pigs were given a single dose of cefuroxime 1500 mg
intravenously immediately before skin incision. The abdominal aorta was exposed through a
25–30 cm long midline laparotomy and the lumbar and inferior mesenteric arteries were
clipped and cut. After an intravenous administration of 5000 IU of heparin, the aorta was
clamped and the infrarenal aorta was replaced by an approximately 5 cm long collagen coated
knitted polyester graft (Gelsoft 8 mm; Vascutek) by end-to-end anastomoses using 4–0 poly-
propylene sutures. Haemostasis was secured and the surface of the graft was directly inoculated
with 106 CFUs of MSSA (ATTC 29219) in 0.3 mL saline solution using a 1-mL syringe. Hereaf-
ter, the retroperitoneum and abdominal wall were closed in layers with standard surgical tech-
niques. All pigs received analgesic treatment with intramuscular injections of flunixin 150 mg
with 24-hour intervals and buprenorphine 0.6 mg with 8-hour intervals for the first three days
after surgery. The day of treatment initiation was defined as baseline (day 0) and therefore the
day of the operation was defined as day -7. Weight and rectal temperature were measured and
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blood samples were collected before the operation (day -7) and at day -6 (only temperature),
-5 (not weight), 0, 7, 14, and 21. These parameters were always obtained in the morning prior
to treatment administration. Healthy pigs gain approximately 0.5–1.0 kilogram per day and
have a normal rectal temperature range of 38.7–39.8 Celsius [28]. The blood samples were
used for analysis of white blood cell count (WBC), haemoglobin (HGB) and haptoglobin—the
latter being an infection marker in pigs and equivalent to C-reactive protein (CRP) in humans.
A decrease in HGB and an increase in WBC and haptoglobin were interpreted as signs of an
ongoing infection. Moreover, the animal keepers recorded several other parameters on an
ordinal scale, such as stool (yes/no), movement (normal/impaired/abnormal), wound appear-
ance (no infection/superficial infection/severe infection), and treatment compliance (eaten/
partially eaten/not eaten/no treatment given) on a daily basis.
Treatment groups, dosages, and administration
Based on human equivalent dosages we initially planned to use a TDZ dosage of 300 mg x 2
daily, which was equivalent to 10 mg/kg/day in a 60 kg pig [29]. However, this had to be consid-
erably reduced due to adverse drug effects. The final treatment regimens used are described
below. The drugs were administered orally in two different treatment groups: 1) DCX (Dicillin
750 mg twice daily) and 2) DCX+TDZ (Dicillin 750 mg twice daily + Thioridazin-neuraxpharm
50 mg twice daily the first four days (day 0–4) and 100 mg twice daily for the rest of the treat-
ment period (day 5–21). To enhance compliance the capsules/tablets were broken/crushed and
mixed with dog food and regular pig food. Treatment was initiated 7 days after the implantation
and inoculation of the aortic graft (day 0) and continued for a further 21 days. The pigs were
consecutively allocated to the treatment groups by a fixed randomisation key (1, 2, 2, 1, 1, 2,. . .)
and the animal keepers selected the pigs for surgery blinded from this random allocation.
Sampling and microbiological analyses
After 21 days of treatment, the pigs were anesthetized and the aortic graft was exposed through
the previous incision under aseptic conditions. A swab with a cotton stick was done from the
surface of the graft and placed in a tube with 1 mL PBS + 0,1% Triton X-100 (Sigma-Aldrich
Corporation, Denmark). Tissue from the perigraft area was randomly sampled and transferred
to a plastic tube with 10 ml isotonic saline (Amgros, Denmark). The aorta was ligated above
and beneath the aortic graft and a minimum of 3 cm of the graft was cut out and transferred to
a plastic tube with 40 ml of isotonic saline. Finally, the pigs were euthanized with an intrave-
nous injection of phenobarbital.
Immediately, the samples were transferred to the laboratory for microbiological analysis.
The swab was vortexed for one minute, and the cotton stick was wiped off on the inside of the
tube before removal. Under aseptic conditions, 1 cm of the graft was cut off and placed in a
tube with 5 ml PBS + 0.1% Triton X-100 and vortexed for 1 min. The tissue was weighed and
homogenized in 10 ml of isotonic saline. All three solutions from the swab, tissue and graft
were individually plated on Mueller-Hinton agar plates in ten-fold serial dilutions for CFU
determination with 0.1 ml on each plate.
Statistical analyses
Bacterial count data from all three primary bacteriological endpoints (graft, swab, and tissue)
were converted into CFU/mL and added by one (+1) to avoid zeros and allow transformation by
natural logarithm (ln). Despite different transformation attempts of the data a normal distribution
could not be achieved and thus, a two-sample Wilcoxon rank-sum (Mann-Whitney) test was
used for comparison. Furthermore, bacterial quantity data from each bacteriological endpoint
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were converted into binary categorical variable and labelled: “No growth” or “Growth” referring
to CFU/mL = 0 or CFU/mL>0, respectively and compared by two-sided Fisher’s exact test.
Mixed models were used in the analysis of longitudinal continuous variables (weight, tempera-
ture, WBC, HGB, and haptoglobin) to pursue individual changes within treatment groups over
time. Determination of the mixed model was based on the research question alone. Treatment
group and time (including interaction) were set as fixed values, and baseline values (day 0) as
covariates. Pig number (ID) was set as the random intercept. Ordinal outcomes of the variables:
defecation, movement, wound healing, and treatment compliance were compared between treat-
ment groups by a Chi-squared test. A p-value of<0.05 was considered significant. Stata/IC ver-
sion 13.1 (Statacorp) was used for illustrations and analyses.
Sample size calculation
Sample size of the study was set upon a power calculation to detect a 50% difference in the fre-
quency of graft infections or a 15% difference in bacterial quantities with an 80% power and a
5% significance level, assuming that 100% of the grafts will be infected by the end of the study
in pigs from the control group (DCX treatment only).
Results
MIC, MBC and viability assay
DCX and TDZ had MIC/MBC-values of 0.5/2 mg/L and 32/64 mg/L, respectively. Results of
the in vitro viability assays are presented in Fig 1. In accordance with the MIC/MBC value the
growth of our MSSA test strain was not inhibited by TDZ (16 mg/L) and revealed the same
growth pattern as for the control (no drug). DCX (0.25 mg/L) slightly affected growth and may
therefore be characterised as a sub-inhibitory concentration. However, the combination of
DCX (0.25 mg/L) and TDZ (16 mg/L) showed a significant and synergetic inhibition of growth
with a reduction of bacterial load of approximately 3 and 4.5 log10 CFU compared to DCX
(0.25 mg/L) or TDZ (16 mg/L) alone, respectively, after 10 hours.
The APVGI porcine model
According to the sample size calculation, 32 pigs were included. Seventeen pigs were allocated
to the combination treatment (DCX+TDX) and 15 pigs to monotherapy (DCX). Three pigs
had to be euthanized before the end of the experiment: two pigs on day 2 due to spinal cord
ischemia (both allocated to the combination treatment), and one pig on day 21 due to persis-
tent high fever (allocated to the DCX-group). In total, 29 pigs (91%) survived until the end of
the experiment with a treatment group distribution of 14 pigs in the DCX-group and 15 pigs
in DCX+TDZ-group. Baseline characteristics before treatment initiation (day 0) of all pigs
were recorded and sorted by treatment group as presented in Table 1. Comparisons of the
treatment groups revealed non-significant p-values for all parameters.
Primary bacteriological endpoints
Following three weeks of conservative treatment with either DCX alone or DCX+TDZ in com-
bination we determined the bacterial quantities from graft surface swabs, graft materials and
perigraft tissue. As shown in Table 2, we found no statistically significant differences in bacte-
rial quantities between the two treatment groups with respect to graft (p = 0.209), swab
(p = 0.864), and tissue (p = 0.728). Some bacterial endpoints actually revealed zero bacterial
counts, and therefore we decided to transform the continuous count data into binary out-
comes of growth vs. no growth for a post hoc analysis. However, we still observed no
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significant difference between the treatment groups. Some of the microbiological analyses
were inconclusive due to contamination of the agar plates and were excluded from the analy-
sis. The number of included observations (N) from each treatment group is displayed in
Table 2.
Secondary longitudinal continuous outcomes
Changes in mean weight, temperature, WBC, HGB, and haptoglobin during the experimental
period for both treatment groups are illustrated in Fig 2A–2E.
Overall, the curves of the two treatment groups had similar shapes and slopes with overlap-
ping standard deviations on all variables. However, the curves of weight, temperature, and
Fig 1. In vitro viability assay: The effect of thioridazine (TDZ) and dicloxacillin (DCX), alone and in combination, on
survival of MSSA (ATCC 29213) over time. Control: No drug.
doi:10.1371/journal.pone.0173362.g001
Table 1. Baseline characteristics, listed for all pigs and by treatment group.
Variables All pigs (n = 29) DCX (n = 14) DCX+TDZ (n = 15) p-value*
Mean (SD)
Weight (kg) 53.7 (2.4) 54.0 (2.8) 53.5 (2.0) 0.58
Temperature (Celsius) 39.2 (0.3) 39.2 (0.3) 39.2 (0.3) 0.75
White blood cell count (109/L) 20.4 (5.9) 20.8 (7.1) 20.1 (4.6) 0.78
Haemoglobin (g/dL) 9.6 (0.7) 9.6 (0.5) 9.6 (0.8) 0.93
Haptoglobin (mg/mL) 3.6 (0.8) 3.4 (0.9) 3.7 (0.8) 0.38
* Comparison of the two treatment groups (DCX vs. DCX+TDZ) by t-test with equal variance at baseline (day 0) immediately before treatment initiation.
doi:10.1371/journal.pone.0173362.t001
Thioridazine and dicloxacillin against aortic graft infections in a porcine model
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haptoglobin slightly diverged from day 0 to day 21, meaning that the DCX-group tended to
have a higher weight and temperature, but a lower level of haptoglobin than the DCX+TDZ-
group toward the end of the treatment period. Furthermore, it is noteworthy that most vari-
ables improved from treatment initiation on day 0 (marked by the grey dotted line) and
onwards, even though WBC increased in both treatment groups from day 0 to 7 and then
decreased from day 7 to 21, and similar HGB initially improved from day 0 to 7 and then
declined from day 7 to 21 (Fig 2C and Fig 2D).
Individual changes of each response variable within treatment groups over time were pur-
sued by mixed model analysis and the coefficients are listed in Table 3.
All mixed model analyses in Table 3 are based on the DCX-group as the reference treatment
group, and because no numeric conversions were made the coefficients are equivalent to the
entities of each variable. The coefficients are best explained by using the response variable weight
as an example. The first coefficient in the weight column explains the difference between the
DCX+TDZ-group and DCX-group at the first time point after baseline, in this case day 7 (DCX
+TDZ–DCX | day 7 = -1.59 kg). The next two coefficients explain the weight changes over time
of the reference treatment group (DCX) compared to the measurement at day 7 and day 14,
respectively (Day 14 –Day 7 | DCX = 7.32 kg; Day 21 –Day 7 | DCX = 11.34 kg. Both time points
showed a highly significant increase in weight compared to day 7 (p0.001). The following two
coefficients explain the difference between the two treatment groups at day 14 and 21 compared
to the difference at day 7. Therefore, to calculate the absolute difference at day 14 and 21, the
first coefficient at day 7 must be added (DCX+TDZ–DCX |day 14 = -0.99 + (-1.59) = -2.58 kg;
DCX+TDZ–DCX |day 21 = -0.77 + (-1.59) = -2.36 kg.
In general, the response variables changed during the treatment period, and the last mea-
surements on day 21 were significantly different from the first measurements after baseline
(day 7) in all response variables. However, the analyses for all response variables presented no
statistical significant differences between the treatment groups. The coefficients in Table 3
roughly correspond to the graphed changes in weight, temperature, WBC, HGB, and hapto-
globin in Fig 2A–2E. However, they are not directly comparable since they are based on two
different statistical analyses and calculations.
Table 2. Primary bacteriological endpoints.
Variables N (DCX/DCX+TDZ) DCX (n = 14) DCX+TDZ(n = 15) P-value
Graft
Mean (SD) 12/13 10.2 (5.9) 8.5 (5.6) 0.209a
Growth / No growth 12/13 10/2 10/3 >0.999b
Swab
Mean (SD) 12/15 6.7 (3.6) 6.4 (3.3) 0.864a
Growth / No growth 12/15 10/2 12/3 >0.999b
Tissue
Mean (SD) 13/15 8.8 (6.9) 8.5 (4.7) 0.728a
Growth / No growth 13/15 9/4 12/3 0.67b
a Two-sample Wilcoxon rank-sum (Mann-Whitney) test
b Two-sided Fisher’s exact test.
Bacterial quantities (ln(CFU/mL) of graft, swab and tissue presented as a mean with standard deviation (SD) and as converted binary outcomes (No growth:
CFU/mL = 0 and Growth: CFU/mL > 0) sorted by treatment group. DCX: Dicloxacillin; TDZ: Thioridazine; N: Number of included observation from each
treatment group.
doi:10.1371/journal.pone.0173362.t002
Thioridazine and dicloxacillin against aortic graft infections in a porcine model
PLOS ONE | DOI:10.1371/journal.pone.0173362 March 9, 2017 7 / 15
Animal welfare and treatment compliance
Over the complete experimental period, the daily registrations of parameters concerning animal
welfare—that is, stool (yes/no), movement (normal/impaired/abnormal), and wound appearance
(no infection/superficial infection/severe infection)—included 413 observations in the DCX-group
and 420 observations in the DCX-TDZ-group. The DCX+TDZ group had two observations of “no
stool”, but all other observations showed daily stools with no significant difference between the
treatment groups (p = 0.161). We registered 14 and 21 observations of impaired movement in the
DCX- and DCX+TDZ-groups, respectively. No observations were categorized as abnormal move-
ment in the DCX-group and only 1 in the DCX+TDZ-group. Overall, we found no significant dif-
ference in the movement parameter between the treatment groups (p = 0.310). Regarding wound
appearance, signs of a superficial infection were evident in 15 and 21 observations in the DCX-
and DCX+TDZ-groups, respectively. Signs of severe infection were not observed in the DCX-
group and only once in the DCX+TDZ-group. Overall, the chi-squared test showed no significant
difference in wound appearance between the treatment groups (p = 0.379).
Registration of treatment compliance (eaten/partially eaten/not eaten/no treatment given)
during the three-week treatment period included 309 observations in the DCX-group and 315
observations in the DCX-TDZ-group. In the DCX-group, the treatment was eaten in 298/309
(96%) observations and only partially or not eaten in 8 and 3 observations, respectively. In the
Fig 2. Changes in weight (A), temperature (B), white blood cell count (WBC) (C), haemoglobin (HGB) (D), and haptoglobin
(E) of each treatment group during the experimental period are displayed as mean values with standard deviation bars at
predefined time points. Graft implantation and inoculation was at day -7 and the dotted grey line indicates treatment initiation at
day 0. Dicloxacillin (DCX); Thioridazine (TDZ)
doi:10.1371/journal.pone.0173362.g002
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DCX+TDZ-group, the treatment was eaten in 296/315 (94%) observations and only partially
or not eaten in 11 and 8 observations, respectively. There were no observations of “no treat-
ment given” in any of the treatment groups. Overall, we found high treatment compliance in
both groups with no statistical difference (p = 0.263).
Adverse drug effects
Shortly after treatment initiation in the pilot study, we observed unexpected severe extrapyra-
midal adverse effects and behavioural changes in the pigs treated with a TDZ dose of 300 mg x
2 daily in combination with DCX. The pigs showed signs varying from dizziness and drowsi-
ness to severe agitation with repetitive compulsive self-destructive behaviour (e.g. licking or
scratching the same spot of the pen walls for several hours resulting in abrasions to the head or
snout). Pigs treated with DCX alone showed no signs of these behavioural changes. In consul-
tation with the supervisory veterinarian, we gradually reduced the dosage of TDZ until these
adverse effects were acceptable in relation to animal welfare and ethical regulations. A TDZ
dose reduction to less than a third of the initial dose was required to reach acceptably low levels
of side effects.
Discussion
This study is the first large-animal model investigation of TDZ used in combination with a β-
lactam antibiotic as conservative systemic treatment against a vascular graft infection caused
by S. aureus. Our in vitro experiments were able to reproduce the previously demonstrated in
vitro synergy of DCX and TDZ against the chosen MSSA test strain, but in our porcine model
the combination treatment failed to eradicate early APVGI caused by 106 CFU of MSSA after
three weeks of conservative systemic treatment. Based on the bacterial quantities of the three
primary bacteriological endpoints, no statistical potentiated or synergetic effect of the combi-
nation treatment was found compared to treatment with DCX alone. We emphasize that both
treatment groups had high treatment compliance with no statistical difference and therefore,
this factor can be ruled out as a potential bias.
Table 3. Mixed model analysis of longitudinal continuous outcomes.
Variables Weight Temp WBC HGB Haptoglobin
Coefficients
Treatment group
DCX+TDZ -1.59 -0.31 -0.89 -0.28 0.20
Time (days)
Day 14 7.32 ** 0.12 -3.17 * -0.54 -0.73 **
Day 21 11.34 ** -0.35* -8.92 ** -2.24 ** -1.26 **
Treatment#Time
DCX+TDZ#Day14 -0.99 -0.02 -1.65 0.17 0.26
DCX+TDZ#Day21 -0.77 0.02 1.09 0.69 0.36
Baseline 1.42 ** 0.13 0.48 ** 0.14 0.32*
Intercept -17.72 34.08 14.56 10.39 1.70
Mixed model analysis of weight, temperature (Temp), white blood cell count (WBC), haemoglobin (HGB) and haptoglobin. Treatment group, time (days),
and the interaction between treatment group and time (Treatment#Time) were set as fixed effects and baseline values at day 0 as covariates. Each
individual pig was set as a random intercept.
*: p<0.05
**: p0.001).
doi:10.1371/journal.pone.0173362.t003
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Before treatment initiation all pigs showed increasing temperature and haptoglobin and
decreasing HBG within the first week after graft implantation and inoculation (Fig 2B, Fig 2D,
and Fig 2E), indicating that APVGI was successfully and consistently established.
The bacteriological results had quite wide ranges, and a few samples within each bacterio-
logical endpoint even showed no bacterial growth, but these findings were present in both
treatment groups with no statistical difference (Table 2). Gao et al. [27], who used the same
APVGI porcine model, bacterial strain and inoculum concentration, also reported large SDs
in bacterial load on graft material of 2.93 (SD: 1.45) log10 CFU equivalent to 6.75 (SD: 3.34) ln
CFU following a treatment regimen, which also failed to eradicate the graft infection. This
indicates that insufficient antimicrobial treatment enhances the influence of intrinsic biologi-
cal variations, which can be expressed as large SDs of quantitative bacteriological endpoints, as
seen in our study.
Most secondary outcomes improved after treatment initiation, indicating some effect of
both treatments, including small differences (especially for weight, temperature, and haptoglo-
bin) between the treatment groups (Fig 2A–2E). However, the mixed model analyses of all sec-
ondary outcomes revealed no significant individual differences between treatment groups
during the treatment period.
Our results are in accordance with the findings of two recent animal studies addressing the
potential of systemic treatment with TDZ in combination with a β-lactam antibiotic against S.
aureus [18, 19]. We have recently published assessments of TDZ as a helper compound to DCX
against methicillin-resistant S. aureus (MRSA) in a modified mouse peritonitis model [18]. No
synergetic effect was found using subcutaneous systemic treatment; however, increased sys-
temic dosages of DCX+TDZ revealed an underpowered tendency towards better antimicrobial
efficacy but also indications of increasing adverse effects [18]. Hahn and colleagues [19] also
failed to show any synergetic effect with systemic treatment (intraperitoneal and subcutaneous
administration) of TDZ in combination with cefazolin against MRSA and MSSA in a mouse
skin infection model. No adverse effects were reported.
In contrast, in vivo synergy of TDZ+DCX against MRSA was confirmed in a C. elegans
model [17] and by local intraperitoneal administration in our modified mouse peritonitis
model [18]. It is noteworthy that the presence of high drug concentrations directly at the infec-
tion site is a recurrent characteristic of these two model designs, and all other animal studies
reporting positive outcomes of the treatment with TDZ alone or in combination with an anti-
biotic [17, 18, 23, 30–33].
The promising in vitro results presented here and in a recently published paper [23], along
with the previous report of TDZ’s anti-biofilm capacity [22], led us to this intriguing idea of
TDZ in combination with a β-lactam antibiotic as a possible new conservative treatment solu-
tion against APVGI caused by MSSA. However, the in vitro activities did not manifest in this
in vivo model using systemic treatment in non-toxic dosages. The reason for this discrepancy
is unknown, but the following speculations could guide the design of further investigations to
clarify the issue. First, we recognize that APVGI is arguably one of the most difficult infections
to eradicate without supplemental surgical intervention, and so far, no valid alternative is avail-
able. Furthermore, we may have used inadequate dosages of DCX. More frequent daily dosages
and intravenous administration were also initially considered, but this was not feasible under
the given experimental conditions. Unexpected severe adverse effects related to the planned
TDZ dose forced us to use a substantially lower dose of TDZ. This may have compromised the
results when compared to the in vitro analyses, but these pre-clinical observations are also vital
to protect human patients. Thus, these unexpected findings highlight the importance of per-
forming pre-clinical investigations in higher ranked animals such as pigs, which are physiolog-
ically and genetically more similar to humans than rodents [34].
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Some reports have demonstrated the ability of TDZ to concentrate in macrophages, which
is mediated by lysosomal trapping [35–37], and we speculate that infections occurring in mac-
rophage-rich tissue, such as lung, kidney, and liver, may be better suited for systemic treatment
with this drug combination. In support of this possibility, Hahn et al. demonstrated reduced
bacterial dissemination to the spleen and kidneys [19]. However, further animal pharmacody-
namic studies are needed to clarify TDZ’s penetration, uptake, and distribution in various tis-
sues and the impact of infection and inflammation on these parameters.
Another explanation of the in vitro/in vivo discrepancy is the possibility of a drug-drug
interaction between TDZ and DCX. A pharmaco-epidemiologic study has recently confirmed
previous reports on DCX’s ability to decrease the effect of liver metabolised drugs such as war-
farin [38]. This interaction is most likely mediated through DCX’s activation of the pregnane
X receptor, resulting in induction of CYP3A4 [39], which in combination with CYP2D6, sig-
nificantly contributes to the metabolism of TDZ [40]. Furthermore, a recent report indicates
that pigs are fast metabolisers of CYP2D6 substrates [41]. Hence, co-administration of DCX
and TDZ in pigs may result in an increased conversion of TDZ into metabolites with poten-
tially lower or no antibacterial activity, but which retain potent neuroleptic effects [42]. This
could also explain the observed lack of antimicrobial synergy and the unexpected severe neu-
rologic side effects at dosages which, from human clinical experience, ought to be well-
tolerated.
Evidently, this limits the potential of TDZ as an antimicrobial helper compound for sys-
temic treatment. However, TDZ as a helper compound to an antibiotic drug could still be use-
ful for local or topical treatment, for example as part of antimicrobial impregnations of
indwelling medical devices or antibacterial ointments against staphylococcal skin infections.
We have just recently published a study showing that the combined loading of DCX + TDZ
into a polymer hybrid silicone catheter material increased the antibacterial efficiency, although
release analyses revealed that this effect was caused by a change in loading kinetics and an
enhanced loading capacity of DCX facilitated by the presence of TDZ [23]. Moreover, the puri-
fied (-) enantiomer of TDZ, also patented under the name JEK47, apparently exhibits a more
favourable toxic profile than its racemate, while maintaining the same antibacterial activity
[43]. JEK47 is a promising agent, although in vivo evidence of its combined activity with DCX
is still lacking.
The idea of enhancing the antimicrobial activity of antibiotics with helper compounds is
far from exhausted. Several other prospects of antimicrobial helper compounds, which share
chemical structural resemblance with phenothiazines, have been identified and investigated as
adjuncts to different antibiotics against S. aureus. A screening for antimicrobial activity of
1,057 previously approved drugs derived from the WHO and US Food and Drug Administra-
tion drug lists, revealed a total of 69 potential non-antibiotic helper compounds that potentiate
the antimicrobial activity of a semi-synthetic tetracycline (minocycline) in vitro [44]. Thirty-
five out of the 69 identified helper compounds demonstrated synergism in combination with
minocycline against S. aureus. Especially, disulfiram (also known as: Antabus) showed a strong
synergetic effect on growth inhibition of both MSSA and MRSA strains, including USA300
[44]. Furthermore, chemically designed 2-Phenylquinolines derivatives have proven to be a
potent new class of S. aureus NorA efflux pump inhibitors [45], and studies on β-lactams in
combination with cyslabdan, produced by Streptomyces sp. K04-0144, have also revealed a con-
siderable reduction in MICs against MRSA [46, 47].
In summary, combining drugs to combat antimicrobial resistance is an intriguing field
with a great clinical potential. However, at the same time it adds to biological complexity, both
in regard to clinical efficacy and host toxicity, thus in vivo studies are demanded. The findings
from this study underline the importance of performing in vivo studies in large animal models,
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which to the highest possible degree mimic conditions in humans, before progressing to
human clinical trials.
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